Amsterdam, Netherlands
Amsterdam, Netherlands

Time filter

Source Type

News Article | May 5, 2017
Site: www.prweb.com

Although more remains to be learned, great advances have recently been made in the understanding of the molecular and genetic bases of disease resistance in plants. It is now time to deploy this knowledge to provide more durable disease resistance. Much of these advances have been enabled by improvements in analytical technologies. In particular, high-throughput DNA sequencing enable detailed analysis of food crops and their pathogens. It is now possible to characterize the resistance gene repertoires of plants and variability in pathogen populations. This information can be used as the foundation for rational deployment of resistance genes to maximize the evolutionary hurdle for pathogens to become virulent. In this webinar, sponsored by Dovetail Genomics, participants will learn about the genetic basis for disease resistance in plants and the value of high-quality reference genomes in crop research and improvement. In addition, participants will take away an understanding of how genomics is speeding up crop breeding programs. The speaker for this event will be Dr. Richard Michelmore of the University of California, Davis. Dr. Michelmore currently is a professor of Genetics in the Departments of Plant Sciences, Molecular & Cellular Biology, and Medical Microbiology & Immunology; and Director of the Genome Center at UC-Davis. He earned his doctorate in natural science from the University of Cambridge. Dr. Michelmore’s research focuses on pathogens, genetic changes resistance in plants and development of disease resistance in crops. LabRoots will host the event May 31, 2017, beginning at 9:00 a.m. PDT, 12:00 p.m. EDT. To read more about this event, learn about the continuing education credits offered, and to register for free, click here. About Dovetail Genomics Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all. The company enables researchers and clinicians to solve complex problems involving de novo assembly, structural variation, microbiome analysis, cancer research, phasing analysis and more by providing them a more comprehensive view of the genome. Its proprietary in vitro proximity ligation approach simplifies genomic discovery by integrating the highest quality long-range genomic information with next-gen sequencing output. Dovetail is based in Santa Cruz, California. For more information on Dovetail, its technology, and service offerings, visit dovetailgenomics.com. Follow Dovetail on Twitter @DTGenomics. About Labroots LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


Van Der Ende A.,Medical Microbiology | Van Der Ende A.,University of Amsterdam
Neurology | Year: 2012

Objective: To evaluate the occurrence, treatment, and outcome of subdural empyema complicating community-acquired bacterial meningitis in adults. Methods: Case series from a prospective nationwide cohort study from Dutch hospitals from 2006 to 2011. Results: Subdural empyema was diagnosed in 28 of 1,034 episodes (2.7%), and was present on admission in 10 episodes and diagnosed during admission in 18. Predisposing conditions were present in 26 patients (93%), and consisted of otitis or sinusitis in 21 patients (75%). In all these patients the otitis or sinusitis spread to the subdural space. Twenty-three patients (82%) presented with neurologic symptoms (paresis, focal seizures, dysesthesia contralateral to the empyema). Streptococcus pneumoniae was identified in 26 patients (93%) and Streptococcus pyogenes in 1 (3%); 1 patient had negative CSF cultures. Clinical course was frequently complicated with seizures (50%), focal neurologic abnormalities (54%), and hearing impairment (39%), causing an unfavorable outcome in 19 episodes (68%). Neurosurgical evacuation of the empyema was performed in = patients, all with considerable midline shift. Conclusions: Although rare, subdural empyema must be considered in patients with communityacquired bacterial meningitis and otitis or sinusitis, focal neurologic deficits, or epileptic seizures. S pneumoniae is the predominant causative organism and neurosurgical intervention should be regarded as first-choice therapy in patients with empyema causing midline shift and focal neurologic abnormalities or a decreased level of consciousness. © 2012 American Academy of Neurology.


ALBANY, New York, February 15, 2017 /PRNewswire/ -- Transparency Market Research points out that the leading players operating in the Global Medical Microbiology Testing Technologies Market Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, and Beckman Coulter, I...


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, today announced that it has entered into translational medicine collaborations with Stanford University School of Medicine and Leiden University Medical Center. The relationships will focus on food allergies in children and on patients with C. difficile infection or graft-versus-host disease, respectively. Both collaborations seek to better understand patterns in the microbiome that may potentially inform clinical responses to therapy. Under the terms of the agreement with Stanford, Vedanta will work in collaboration with Kari Nadeau, MD, PhD, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, to analyze the potential connection between the gut microbiome and responses to oral immunotherapies in children with food allergies. With Leiden University, Vedanta will generate clinical data from interventional studies of fecal transplantation in C. difficile patients treated with donors from the Netherlands Donor Feces Bank, as well as clinical data from patients with graft-versus-host disease, in collaboration with Ed Kuijper, MD, PhD, Professor of Medical Microbiology at the Leiden University Medical Center and co-chair of the Netherlands Donor Feces Bank. The clinical data will feed into Vedanta’s leading platform for discovery, development, and GMP manufacturing of rationally designed bacterial consortia drugs. “We’re excited to announce our relationships with Stanford and Leiden University,” said Bruce Roberts, PhD, Chief Scientific Officer of Vedanta Biosciences. “Collaborations with leading academic centers are an important part of our strategy to support our drug development efforts with human data and with careful science.” About Vedanta Biosciences Vedanta Biosciences is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in the first half of 2017. Founded by PureTech Health (PureTech Health plc, PRTC.L) and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia. Leveraging its proprietary technology platform and the expertise of its team of scientific co-founders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterized how the immune system recognizes and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells and Th17 cells, among others – as well as the characterization of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomized, controlled trials in infectious disease and inflammatory bowel disease. Vedanta Biosciences’ scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University). Vedanta is backed by PureTech Health, Seventure, Invesco Asset Management, and Rock Springs Capital. Forward Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.


Ocean View, Delaware, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Clinical Laboratory Services Market size was USD 196.9 billion in 2015, with 6.4% CAGR estimation from 2016 to 2024; as per a new research report by Global Market Insights, Inc. Growing importance of early diagnosis of chronic diseases related to oncology, gynaecology and endocrinology should drive global clinical laboratory services market size. Moreover, introduction of technologically advanced products rendering accurate and rapid results should spur industry growth over the forecast years. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/807 Increased adoption of laboratory automations and robot assisted laboratory techniques such as TECAN liquid handling robotics will spur growth.  For instance, over 30% of laboratories in North America, Europe and Japan have implemented a significant degree of laboratory automation. Additionally, growing use of healthcare IT systems have enabled implementation of technologically advanced processes. Introduction of innovative solutions that allows implementation of informatics and data management systems to perform rapid and seamless operations with accurate clinical results with higher efficiency will accelerate industry growth. Chemistry segment held the largest clinical laboratory services market share with revenue slated to exceed USD 152 billion by 2024. Increasing prevalence of cardiovascular, diabetes, liver & kidney disorders coupled with growing awareness for early diagnosis will spur industry growth. U.S. held the largest share owing to high patient awareness and presence of large test volumes. APAC and LATAM will provide lucrative growth opportunities to industry players with introduction of regulatory standards to encourage the use of clinical laboratory services in these regions. Accounting for over one third of the global population, India and China are eyed upon as potential business hubs for clinical laboratory testing service providers. The key industry players include Quest Diagnostics, Sonic Healthcare, LabCorp, Genoptix Medical Laboratory, Healthscope, Labco, Charles River Laboratories and Bio-Reference Laboratories, Abbott Laboratories. The key strategies of mergers and acquisitions and strategic collaborations will enable industry players to strengthen their regional presence. Browse key industry insights spread across 110 pages with 33 market data tables & 10 figures & charts from the report, “Clinical Laboratory Services Market Size By Test (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Test), By Service Provider (Hospitals, Stand-Alone Laboratories, Clinics), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/807 Clinical laboratory services market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD billion from 2012 to 2024 , for the following segments: The above information is provided on a regional and country basis for the following: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | November 16, 2016
Site: www.newsmaker.com.au

Clinical Laboratory Services Market size is estimated to reach USD 342.3 billion by 2024; as per a new research report by Global Market Insights, Inc. Growing importance of early diagnosis of chronic diseases related to oncology, gynaecology and endocrinology should drive global clinical laboratory services market size. Moreover, introduction of technologically advanced products rendering accurate and rapid results should spur industry growth over the forecast years. Increased adoption of laboratory automations and robot assisted laboratory techniques such as TECAN liquid handling robotics will spur growth.  For instance, over 30% of laboratories in North America, Europe and Japan have implemented a significant degree of laboratory automation. Additionally, growing use of healthcare IT systems have enabled implementation of technologically advanced processes. Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/807 Introduction of innovative solutions that allows implementation of informatics and data management systems to perform rapid and seamless operations with accurate clinical results with higher efficiency will accelerate industry growth. Chemistry segment held the largest clinical laboratory services market share with revenue slated to exceed USD 152 billion by 2024. Increasing prevalence of cardiovascular, diabetes, liver & kidney disorders coupled with growing awareness for early diagnosis will spur industry growth. U.S. held the largest share owing to high patient awareness and presence of large test volumes. APAC and LATAM will provide lucrative growth opportunities to industry players with introduction of regulatory standards to encourage the use of clinical laboratory services in these regions. Accounting for over one third of the global population, India and China are eyed upon as potential business hubs for clinical laboratory testing service providers. The key industry players include Quest Diagnostics, Sonic Healthcare, LabCorp, Genoptix Medical Laboratory, Healthscope, Labco, Charles River Laboratories and Bio-Reference Laboratories, Abbott Laboratories. The key strategies of mergers and acquisitions and strategic collaborations will enable industry players to strengthen their regional presence. Browse key industry insights spread across 110 pages with 33 market data tables & 10 figures & charts from the report, “Clinical Laboratory Services Market Size By Test (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Test), By Service Provider (Hospitals, Stand-Alone Laboratories, Clinics), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


SALT LAKE CITY, UT--(Marketwired - November 08, 2016) - "I'm honored and sort of overwhelmed," responded Marc Couturier, PhD, D(ABMM), after learning that the American Society for Microbiology (ASM) was awarding him the 2017 Diagnostics Young Investigator Award. "I've seen the list of those who have received it previously, and these are some pretty big shoes to fill. The bar is set quite high for the work I have ahead of me," adds Couturier, who is a medical director at ARUP Laboratories in Salt Lake City. He directs ARUP's Parasitology/Fecal Testing, Infectious Disease & Rapid Testing, and Microbial Immunology laboratories and is an associate professor of pathology at the University of Utah. While Couturier is thinking about the work ahead of him, it is the work he has accomplished thus far that has earned him recognition from his peers. Colleagues nominate candidates. "He is well respected and has contributed greatly to field of diagnostic microbiology," says Michael Loeffelholz, PhD, D(ABMM), director of the Clinical Microbiology Laboratory at the University of Texas Medical Branch. He notes the visibility of Couturier's contributions through high-impact publications, presentations at national conferences, committee contributions, and relevant input in listserv forums. "Dr. Couturier is well known for his clinical and translational studies," adds Carey-Ann Burnham, PhD, D(ABMM), an associate professor of pathology and immunology at Washington University, St. Louis School of Medicine. She refers to Couturier's research on Campylobacter and Helicobacter, specifically a paper he authored on Campylobacter diagnosis with an antigen detection assay and a review article on the diagnosis of H. pylori infection. "These are important contributions to the literature, as these areas are controversial; frequently inappropriate laboratory testing is used in the work-up of these infections." In addition to research contributions, Burnham emphasizes his education contributions to the field. She and Couturier are co-editors for Medical Microbiology Question of the Day, an educational resource with more than 5,000 worldwide subscribers. According to ASM, the Diagnostics Young Investigator Award recognizes research excellence and potential to further the educational or research objectives of an outstanding young clinical scientist. Dr. Couturier will be presented with the award in June at the ASM Microbe 2017 conference in New Orleans. "I think my work at a national reference laboratory involves a lot of educating, which may reach a broader audience than that of traditional researchers," says Couturier, reflecting on what is unique about his contributions. "It's work that is changing the way people think about new laboratory tests and how they view test utilization; it moves the analytical focus forward to discussing actual use of the test." Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.


Children with burn wounds are particularly susceptible to bacterial infections because of their immature immune systems. Such infections can slow wound healing, leading to longer hospital stays as well as increased risk of permanent scarring. In severe cases, burn infection can lead to sepsis, which can kill. It is currently extremely difficult for doctors to diagnose infections quickly and at the patient's bedside. Existing methods take up to 48 hours and require removing the wound dressing which is painful and distressing for the patient and may result in slower healing and potentially life-long scarring. Due to this time delay, when a child with a burn shows symptoms of a possible infection, the clinician often has to treat them with antibiotics as a precaution before their infection is confirmed. However, treatment with antibiotics when there is no infection can lead to bacteria becoming resistant to antibiotics. Antibiotic resistance has been identified by world leaders as one of the biggest health threats we face today. Scientists from the Department of Chemistry, in collaboration with the Healing Foundation Children's Burns Research Centre, based at the Bristol Children's Hospital, and the University of Brighton have developed a prototype dressing that will change colour as soon as the wound is infected. This will enable doctors to quickly treat only those patients with an infection, without giving unnecessary antibiotics to patients who may simply have symptoms due to a cold. Dr Toby Jenkins, Reader in Biophysical Chemistry at Bath leading the project, explained: "Our medical dressing works by releasing fluorescent dye from nanocapsules triggered by the toxins secreted by disease-causing bacteria within the wound. "The nanocapsules mimic skin cells in that they only break open when toxic bacteria are present; they aren't affected by the harmless bacteria that normally live on healthy skin. "Using this dressing will allow clinicians to quickly identify infections without removing it, meaning that patients can be diagnosed and treated faster. It could really help to save lives." Taking research from the lab to the clinic The team has been awarded almost £1 million by the Medical Research Council, through the Biomedical Catalyst funding stream, to test the responsiveness of the prototype dressing to samples taken from the wounds of burns victims. Dr Jenkins commented: "Translating research from the laboratory towards the clinic is fraught with complexity, but this award will allow us to start this critical translational pathway. Working with our industry partner, the funding will be used to design, manufacture and package a final prototype dressing, safe and ready for trial in humans." Dr Amber Young is the Clinical Lead for the Healing Foundation Children's Burns Research Centre at Bristol Children's Hospital. She will be taking wound swabs and blister fluid from young burns patients and linking these to patients' symptoms for Dr Jenkins to test how well the new dressing detects infection in samples from real patients. She said: "Children are at particular risk of serious infection from even a small burn. However, with current methods clinicians can't tell whether a sick child might have a raised temperature due to a serious bacterial burn wound infection, or just from a simple cough or cold. "Being able to detect infection quickly and accurately with this wound dressing will make a real difference to the lives of thousands of young children by allowing doctors to provide the right care at the right time, and also, importantly, reduce the global threat of antibiotic resistance." Dr Brian Jones, Reader in Molecular and Medical Microbiology from the University of Brighton, will be coordinating work to understand and optimise how the dressing responds to problematic bacteria in wounds, and also to collect samples from adult patients at Queen Victoria Hospital in West Sussex. Dr Jones added: "This new dressing technology will not only help clinicians provide the best possible treatment for patients with burns, but could also tell us a lot about how wound infections begin and how they affect the normal healing process. This could in turn lead to even further advances in treating these infections." Once the dressing has been proven to effectively detect infection in swab samples from patients, the team plans to work with healthcare company Hartmann to develop the dressing for use in hospitals in around four years. Explore further: Revolutionary medical dressing uses nano-technology to fight infection


News Article | November 16, 2015
Site: www.cemag.us

Children with burn wounds are particularly susceptible to bacterial infections because of their immature immune systems. Such infections can slow wound healing, leading to longer hospital stays as well as increased risk of permanent scarring. In severe cases, burn infection can lead to sepsis, which can kill. It is currently extremely difficult for doctors to diagnose infections quickly and at the patient’s bedside. Existing methods take up to 48 hours and require removing the wound dressing which is painful and distressing for the patient and may result in slower healing and potentially life-long scarring. Due to this time delay, when a child with a burn shows symptoms of a possible infection, the clinician often has to treat them with antibiotics as a precaution before their infection is confirmed. However, treatment with antibiotics when there is no infection can lead to bacteria becoming resistant to antibiotics. Antibiotic resistance has been identified by world leaders as one of the biggest health threats we face today. Scientists from the Department of Chemistry at the University of Bath, in collaboration with the Healing Foundation Children’s Burns Research Centre based at the Bristol Children’s Hospital, and the University of Brighton have developed a prototype dressing that will change color as soon as the wound is infected. This will enable doctors to quickly treat only those patients with an infection, without giving unnecessary antibiotics to patients who may simply have symptoms due to a cold. Dr. Toby Jenkins, Reader in Biophysical Chemistry at Bath leading the project, explains, “Our medical dressing works by releasing fluorescent dye from nanocapsules triggered by the toxins secreted by disease-causing bacteria within the wound. “The nanocapsules mimic skin cells in that they only break open when toxic bacteria are present; they aren’t affected by the harmless bacteria that normally live on healthy skin. “Using this dressing will allow clinicians to quickly identify infections without removing it, meaning that patients can be diagnosed and treated faster. It could really help to save lives.” The team has been awarded almost $1.5 million by the Medical Research Council, through the Biomedical Catalyst funding stream, to test the responsiveness of the prototype dressing to samples taken from the wounds of burns victims. Jenkins says, “Translating research from the laboratory towards the clinic is fraught with complexity, but this award will allow us to start this critical translational pathway. Working with our industry partner, the funding will be used to design, manufacture and package a final prototype dressing, safe and ready for trial in humans.” Dr. Amber Young is the Clinical Lead for the Healing Foundation Children’s Burns Research Centre at Bristol Children’s Hospital. She will be taking wound swabs and blister fluid from young burns patients and linking these to patients’ symptoms for Jenkins to test how well the new dressing detects infection in samples from real patients. She says, “Children are at particular risk of serious infection from even a small burn. However, with current methods clinicians can’t tell whether a sick child might have a raised temperature due to a serious bacterial burn wound infection, or just from a simple cough or cold. “Being able to detect infection quickly and accurately with this wound dressing will make a real difference to the lives of thousands of young children by allowing doctors to provide the right care at the right time, and also, importantly, reduce the global threat of antibiotic resistance.” Dr. Brian Jones, Reader in Molecular and Medical Microbiology from the University of Brighton, will be coordinating work to understand and optimize how the dressing responds to problematic bacteria in wounds, and also to collect samples from adult patients at Queen Victoria Hospital in West Sussex. “This new dressing technology will not only help clinicians provide the best possible treatment for patients with burns, but could also tell us a lot about how wound infections begin and how they affect the normal healing process. This could in turn lead to even further advances in treating these infections,” says Jones. Once the dressing has been proven to effectively detect infection in swab samples from patients, the team plans to work with healthcare company Hartmann to develop the dressing for use in hospitals in around four years. Release Date: November 16, 2015 Source: University of Bath


Pope C.F.,Medical Microbiology
Methods in molecular biology (Clifton, N.J.) | Year: 2010

Acquisition of antibiotic resistance may be associated with a physiological cost for the bacterium. Determination of growth rate and generation time is often used to measure fitness costs associated with antibiotic resistance. However, fitness costs may be small and difficult to quantify and multiple models are required. Available in vitro models that can be used to measure fitness include quantification of biofilm growth, survival in water, resistance to drying, and measurement of planktonic growth rates. The use of growth curve techniques to determine generation time is laborious, time-consuming, and can introduce sampling error. We have described the use of a semi-automated liquid culture system to estimate generation time in Burkholderia cepacia complex bacteria. We have also used the BacT/ALERT system to determine generation time and enumerate bacterial numbers in Mycobacterium tuberculosis. We describe methods for measuring biofilm growth and environmental survival in Burkholderia cepacia complex bacteria. These methods can be adapted for use with other organisms.

Loading Medical Microbiology collaborators
Loading Medical Microbiology collaborators